Chest
Selected ReportsTubulointerstitial Nephritis Induced by the Leukotriene Receptor Antagonist Pranlukast
Section snippets
CASE REPORT
A 7-year-old white boy with a 4-year history of moderate persistent asthma was enrolled via the University of South Florida (Tampa) division of Allergy and Immunology in a double-blind, placebo-controlled clinical trial of pranlukast. Prior to study enrollment, therapy for asthma included nebulized albuterol 2 to 4 times daily. Acute exacerbations 1 and 18 months prior to enrollment required 5 days of pulse therapy with oral prednisolone, but he was not receiving other corticosteroid therapy.
DISCUSSION
Binding of the single leukotriene receptor present in human bronchial smooth muscle by the cysteinyl-leukotrienes (LTC4, LTD4, and LTE4) contributes to the immediate and long-term bronchoconstriction, microvascular permeability, mucus secretion, and eosinophil influx that mediates the airway obstruction present in patients with asthma.1 Experimental evidence in animals and humans indicates that pranlukast significantly reduces these responses, and clinical trials have demonstrated that
REFERENCES (7)
Pharmacology of leukotriene receptor antagonists: more than inhibitors of bronchoconstriction
Chest
(1997)Leukotrienes in the pathogenesis of asthma
Chest
(1997)- et al.
Worldwide clinical experience with the first marketed leukotriene receptor antagonist
Chest
(1997)
Cited by (13)
Antileukotriene drugs in asthmatic preschool children
2004, Revue Francaise d'Allergologie et d'Immunologie CliniqueEfficacy and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene-receptor antagonist: Four-year followup study
2001, Annals of Allergy, Asthma and ImmunologyPlace of leukotriene inhibitor therapy in the treatment of asthma in childhood
2000, Archives de PediatrieAcute tubulointerstitial nephritis
2012, Pediatric NephrologyWhat is the Role of Leukotriene Modifiers in the Treatment of Asthma?
2008, Asthma: Critical Debates